1,25-dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade

Ananya Datta-Mitra, Anupam Mitra, Rahul Ray, Siba P Raychaudhuri, Smriti Kundu-Raychaudhuri

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose The molecular mechanism responsible for the immunomodulatory effect of 1,25-dihydroxyvitamin D3 (Vit-D) is still not well elucidated. Unavoidable systemic toxicity of Vit-D has encouraged to develop more potent and less toxic Vit-D analogs, such as 1,25-dihydroxyvitamin D3-3-bromoacetate (BE). Our aim was to explore the immunosuppressive effect of BE and its molecular mechanism in autoimmune diseases. Method Magnetically sorted CD3+ T cells (T cells) from PBMCs of psoriasis and autoimmune arthritis patients were cultured with/without BE and Vit-D followed by proliferation (MTT, CFSE dilution assays) and apoptosis assays (annexin V). Immunoblot was performed to determine the signaling cascade responsible for the antiproliferative effect. Results In MTT assay, BE (OD: 0.64 ± 0.08) markedly inhibited the anti-CD3/CD28 stimulated proliferation of T cells (OD: 1.8 ± 0.30, p < 0.001) and at equivalent doses, the inhibitory effect was more than that of Vit-D (OD: 0.91 ± 0.11, p < 0.05). The antiproliferative effect of BE was extended to activated CD4+ and CD8+ memory T cells (CD45RA -CD11a+) without much effect on the naïve T cells. BE induced more apoptosis of T cells (45.01 ± 4.27%, p < 0.01) compared to untreated cells (3.45 ± 1.8%), and the proapoptotic effect was markedly more than that of Vit-D (26.1 ± 2.05%, p < 0.05). BE effectively inhibited the anti-CD3/CD28-induced phosphorylation of Akt and mTOR and in both, BE showed more potency than Vit-D (p < 0.05). Conclusion Topical Vit-D is being used successfully in psoriasis for years. However, its potency is less compared to topical corticosteroids. The de novo BE showed significantly more immunosuppression than conventional Vit-D and the immunosuppressive effect is PI3K/Akt/mTOR dependent. Our results indicate that BE could be an effective therapeutic agent for psoriasis and other T-cell-mediated autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)744-751
Number of pages8
JournalInternational Immunopharmacology
Volume17
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Phosphatidylinositol 3-Kinases
Vitamin D
Immunosuppression
T-Lymphocytes
Psoriasis
Immunosuppressive Agents
Autoimmune Diseases
Apoptosis
bromoacetate
1,25-dihydroxyvitamin D3-3-bromoacetate
Calcitriol
Poisons
Annexin A5
Arthritis
Adrenal Cortex Hormones
Phosphorylation

Keywords

  • 1α,25-dihydroxyvitamin D3-3-bromoacetate
  • Akt/mTOR
  • Proliferation
  • T cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

1,25-dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade. / Datta-Mitra, Ananya; Mitra, Anupam; Ray, Rahul; Raychaudhuri, Siba P; Kundu-Raychaudhuri, Smriti.

In: International Immunopharmacology, Vol. 17, No. 3, 2013, p. 744-751.

Research output: Contribution to journalArticle

Datta-Mitra, Ananya ; Mitra, Anupam ; Ray, Rahul ; Raychaudhuri, Siba P ; Kundu-Raychaudhuri, Smriti. / 1,25-dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade. In: International Immunopharmacology. 2013 ; Vol. 17, No. 3. pp. 744-751.
@article{e90abf85d5364a0aadd6b286388e356f,
title = "1,25-dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade",
abstract = "Purpose The molecular mechanism responsible for the immunomodulatory effect of 1,25-dihydroxyvitamin D3 (Vit-D) is still not well elucidated. Unavoidable systemic toxicity of Vit-D has encouraged to develop more potent and less toxic Vit-D analogs, such as 1,25-dihydroxyvitamin D3-3-bromoacetate (BE). Our aim was to explore the immunosuppressive effect of BE and its molecular mechanism in autoimmune diseases. Method Magnetically sorted CD3+ T cells (T cells) from PBMCs of psoriasis and autoimmune arthritis patients were cultured with/without BE and Vit-D followed by proliferation (MTT, CFSE dilution assays) and apoptosis assays (annexin V). Immunoblot was performed to determine the signaling cascade responsible for the antiproliferative effect. Results In MTT assay, BE (OD: 0.64 ± 0.08) markedly inhibited the anti-CD3/CD28 stimulated proliferation of T cells (OD: 1.8 ± 0.30, p < 0.001) and at equivalent doses, the inhibitory effect was more than that of Vit-D (OD: 0.91 ± 0.11, p < 0.05). The antiproliferative effect of BE was extended to activated CD4+ and CD8+ memory T cells (CD45RA -CD11a+) without much effect on the na{\"i}ve T cells. BE induced more apoptosis of T cells (45.01 ± 4.27{\%}, p < 0.01) compared to untreated cells (3.45 ± 1.8{\%}), and the proapoptotic effect was markedly more than that of Vit-D (26.1 ± 2.05{\%}, p < 0.05). BE effectively inhibited the anti-CD3/CD28-induced phosphorylation of Akt and mTOR and in both, BE showed more potency than Vit-D (p < 0.05). Conclusion Topical Vit-D is being used successfully in psoriasis for years. However, its potency is less compared to topical corticosteroids. The de novo BE showed significantly more immunosuppression than conventional Vit-D and the immunosuppressive effect is PI3K/Akt/mTOR dependent. Our results indicate that BE could be an effective therapeutic agent for psoriasis and other T-cell-mediated autoimmune diseases.",
keywords = "1α,25-dihydroxyvitamin D3-3-bromoacetate, Akt/mTOR, Proliferation, T cells",
author = "Ananya Datta-Mitra and Anupam Mitra and Rahul Ray and Raychaudhuri, {Siba P} and Smriti Kundu-Raychaudhuri",
year = "2013",
doi = "10.1016/j.intimp.2013.08.009",
language = "English (US)",
volume = "17",
pages = "744--751",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - 1,25-dihydroxyvitamin D3-3-bromoacetate, a novel vitamin D analog induces immunosuppression through PI3K/Akt/mTOR signaling cascade

AU - Datta-Mitra, Ananya

AU - Mitra, Anupam

AU - Ray, Rahul

AU - Raychaudhuri, Siba P

AU - Kundu-Raychaudhuri, Smriti

PY - 2013

Y1 - 2013

N2 - Purpose The molecular mechanism responsible for the immunomodulatory effect of 1,25-dihydroxyvitamin D3 (Vit-D) is still not well elucidated. Unavoidable systemic toxicity of Vit-D has encouraged to develop more potent and less toxic Vit-D analogs, such as 1,25-dihydroxyvitamin D3-3-bromoacetate (BE). Our aim was to explore the immunosuppressive effect of BE and its molecular mechanism in autoimmune diseases. Method Magnetically sorted CD3+ T cells (T cells) from PBMCs of psoriasis and autoimmune arthritis patients were cultured with/without BE and Vit-D followed by proliferation (MTT, CFSE dilution assays) and apoptosis assays (annexin V). Immunoblot was performed to determine the signaling cascade responsible for the antiproliferative effect. Results In MTT assay, BE (OD: 0.64 ± 0.08) markedly inhibited the anti-CD3/CD28 stimulated proliferation of T cells (OD: 1.8 ± 0.30, p < 0.001) and at equivalent doses, the inhibitory effect was more than that of Vit-D (OD: 0.91 ± 0.11, p < 0.05). The antiproliferative effect of BE was extended to activated CD4+ and CD8+ memory T cells (CD45RA -CD11a+) without much effect on the naïve T cells. BE induced more apoptosis of T cells (45.01 ± 4.27%, p < 0.01) compared to untreated cells (3.45 ± 1.8%), and the proapoptotic effect was markedly more than that of Vit-D (26.1 ± 2.05%, p < 0.05). BE effectively inhibited the anti-CD3/CD28-induced phosphorylation of Akt and mTOR and in both, BE showed more potency than Vit-D (p < 0.05). Conclusion Topical Vit-D is being used successfully in psoriasis for years. However, its potency is less compared to topical corticosteroids. The de novo BE showed significantly more immunosuppression than conventional Vit-D and the immunosuppressive effect is PI3K/Akt/mTOR dependent. Our results indicate that BE could be an effective therapeutic agent for psoriasis and other T-cell-mediated autoimmune diseases.

AB - Purpose The molecular mechanism responsible for the immunomodulatory effect of 1,25-dihydroxyvitamin D3 (Vit-D) is still not well elucidated. Unavoidable systemic toxicity of Vit-D has encouraged to develop more potent and less toxic Vit-D analogs, such as 1,25-dihydroxyvitamin D3-3-bromoacetate (BE). Our aim was to explore the immunosuppressive effect of BE and its molecular mechanism in autoimmune diseases. Method Magnetically sorted CD3+ T cells (T cells) from PBMCs of psoriasis and autoimmune arthritis patients were cultured with/without BE and Vit-D followed by proliferation (MTT, CFSE dilution assays) and apoptosis assays (annexin V). Immunoblot was performed to determine the signaling cascade responsible for the antiproliferative effect. Results In MTT assay, BE (OD: 0.64 ± 0.08) markedly inhibited the anti-CD3/CD28 stimulated proliferation of T cells (OD: 1.8 ± 0.30, p < 0.001) and at equivalent doses, the inhibitory effect was more than that of Vit-D (OD: 0.91 ± 0.11, p < 0.05). The antiproliferative effect of BE was extended to activated CD4+ and CD8+ memory T cells (CD45RA -CD11a+) without much effect on the naïve T cells. BE induced more apoptosis of T cells (45.01 ± 4.27%, p < 0.01) compared to untreated cells (3.45 ± 1.8%), and the proapoptotic effect was markedly more than that of Vit-D (26.1 ± 2.05%, p < 0.05). BE effectively inhibited the anti-CD3/CD28-induced phosphorylation of Akt and mTOR and in both, BE showed more potency than Vit-D (p < 0.05). Conclusion Topical Vit-D is being used successfully in psoriasis for years. However, its potency is less compared to topical corticosteroids. The de novo BE showed significantly more immunosuppression than conventional Vit-D and the immunosuppressive effect is PI3K/Akt/mTOR dependent. Our results indicate that BE could be an effective therapeutic agent for psoriasis and other T-cell-mediated autoimmune diseases.

KW - 1α,25-dihydroxyvitamin D3-3-bromoacetate

KW - Akt/mTOR

KW - Proliferation

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=84884476877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884476877&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2013.08.009

DO - 10.1016/j.intimp.2013.08.009

M3 - Article

C2 - 24036370

AN - SCOPUS:84884476877

VL - 17

SP - 744

EP - 751

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 3

ER -